fbpx
QQQ
+ 3.21
341.15
+ 0.93%
DIA
+ 0.69
338.09
+ 0.2%
SPY
+ 2.27
418.59
+ 0.54%
TLT
+ 0.35
142.94
+ 0.24%
GLD
-0.70
167.65
-0.42%

Idrasil Could Be The First Standardized Medical Marijuana Prescription Pill

November 18, 2018 3:56 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Steele Clarke Smith III is chairman and CEO of C3 International, a post-proof of concept, pre-revenue life sciences company specializing in cannabinoid therapeutics.

C3 achieved proof of concept in 2015.

“I have been in the financial markets ever since, raising the massive amount of capital necessary to build out a GMP manufacturing facility with an ISO-9001 laboratory to produce Idrasil," Smith told Green Entrepreneur during a recent chat.

“Idrasil is born out of necessity from the market's lack of a whole, natural and active, standardized and consistent, divisible and titratable cannabis tablet." 

C3's pioneering patient, a 21-year-old San Diego man, came monthly from San Diego for raw cannabis and capsules prepared for him, Smith said. The patient was on an organ transplant list and marked the first reimbursement the company received for medical cannabis in 2007, he said. 

The Backstory

Smith and his wife Theresa were indicted for the illegal cultivation of 20,000 marijuana plants on Nov. 1, 2007. As part of a wider DEA operation in Southern California, 46 other early dispensary owners were also indicted.

The other dispensary owners faced other charges in addition to cultivation and were ultimately convicted, Smith said. 

“We only had two charges: cultivation and conspiracy to cultivate. Those charges were ultimately dropped because of our strict compliance with California state law and successful threat to invoke the Fourth Amendment of the U.S. Constitution at trial, which never happened. We ultimately [pleaded] guilty to a lesser charge." 

After the case ended in 2012, Smith said he decided to develop C3 into a "sophisticated biopharmaceutical company." 

C3 is focused on the production of Idrasil, which the company defines as "the first Rx cannabis tablet." The company said Idrasil can be reimbursed by insurance and urges patients to ask their doctors about the pill. 

Prescription Cannabis?

What does it mean that Idrasil is a standardized pill? What makes it a prescription pill?

“Standardized means doseable,” Smith said. “Doseable means titratable. And, titratable means: milligrams over body weight over time.”

The Rx component derives from Idrasil’s positioning as a pharmaceutical product rather than an over-the-counter pill. C3 intends to pursue FDA approval by 2020, Smith said. 

I developed Idrasil because I am a patient. The best way for patients like me with Crohn's disease to benefit from cannabis is orally, via the hepatic process, which is the only method of ingestion that delivers metabolized cannabinoids to the bloodstream." 

C3 has raised $33 million to date. Stay tuned for further updates. 

Related Links:

MariMed, GenCanna Flobal Form Hemp Partnership

Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week 

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

'The Breakfast Club's' Charlamagne Tha God Says 'Not Legalizing Cannabis Is Hypocritical'

Despite never being an avid cannabis consumer, Charlamagne Tha God, controversial co-host of the nationally syndicated radio show The Breakfast Club, television personality, actor and best-s read more

Pennsylvania's Cannabis Market: What Investors And Entrepreneurs Need To Know

Pennsylvania's medical cannabis market has been one of the better success stories in the industry to date. read more

Missouri's Cannabis Market: What Investors And Entrepreneurs Need To Know

Missouri often gets lost in the shuffle when discussing U.S. cannabis. Those ignoring the Show-Me State and its medical market may be missing an early opportunity as an investor or entrepreneur. read more